Trial · NCT04168385
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: ALGS | At least one TEAE | 36 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: PFIC | At least one TEAE | 12 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: ALGS | TEAE ≥ 3 | 9 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: PFIC | TEAE ≥ 3 | 4 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: ALGS | Serious TEAE | 10 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: PFIC | Serious TEAE | 3 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: ALGS | Serious Treatment-Related Adverse Event | 0 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: PFIC | Serious Treatment-Related Adverse Event | 0 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: ALGS | Serious Treatment-Related TEAE | 0 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: PFIC | Serious Treatment-Related TEAE | 0 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: ALGS | TEAE Leading to Discontinuation of Study Drug | 3 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: PFIC | TEAE Leading to Discontinuation of Study Drug | 1 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: ALGS | TEAE Leading to Death | 1 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: PFIC | TEAE Leading to Death | 0 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: ALGS | Treatment-emergent AESI | 0 | Participants | |
| Incidence of Treatment-Emergent Adverse Events | Maralixibat: PFIC | Treatment-emergent AESI | 1 | Participants | |
| Long-Term Effect on Pruritus | Maralixibat: ALGS | -0.4 | Standard Deviation 0.89 | score on a scale | |
| Long-Term Effect on Pruritus | Maralixibat: PFIC | -0.3 | Standard Deviation 1.12 | score on a scale | |
| Long-Term Effect on Serum Bile Acid Levels | Maralixibat: ALGS | -15.948 | Standard Deviation 31.4239 | µmol/L | |
| Long-Term Effect on Serum Bile Acid Levels | Maralixibat: PFIC | -82.647 | Standard Deviation 136.4354 | µmol/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04168385/results